Sep 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Sep 25, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Sep 24, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
Sep 23, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
Sep 18, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
Sep 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.